2:58 PM
Nov 14, 2017
 |  BC Innovations  |  Distillery Therapeutics


INDICATION: Brain cancer; prostate cancer

Cell culture and mouse studies suggest Bcl-XL inhibitors could help treat glioma, prostate and other cancers harboring the IDH1 R123H mutation. In human glioma and prostate cancer cell lines, cells engineered to express the IDH1 R132H mutation were more sensitive to the Bcl-XL/BCL-2 inhibitor navitoclax than the corresponding cell lines expressing wild-type IDH1. Also in the cell lines, siRNA targeting Bcl-XL increased apoptosis of...

Read the full 320 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$18 USD
More Info >